

REVIEW

Open Access

# Role of IL-17 family cytokines in the progression of IPF from inflammation to fibrosis

Yun-Juan Nie<sup>1</sup>, Shuo-Hua Wu<sup>2</sup>, Ying-Hua Xuan<sup>3</sup> and Gen Yan<sup>4\*</sup>

## Abstract

Idiopathic pulmonary fibrosis (IPF) is a fatal chronic interstitial lung disease with no established treatment and is characterized by progressive scarring of the lung tissue and an irreversible decline in lung function. Chronic inflammation has been demonstrated to be the pathological basis of fibrosis. Emerging studies have revealed that most interleukin-17 (IL-17) isoforms are essential for the mediation of acute and chronic inflammation via innate and adaptive immunity. Overexpression or aberrant expression of IL-17 cytokines contributes to various pathological outcomes, including the initiation and exacerbation of IPF. Here, we aim to provide an overview of IL-17 family members in the pathogenesis of IPF.

**Key words** Interleukin-17 (IL-17) family, IL-17 receptor, Inflammation, Idiopathic pulmonary fibrosis

## Background

Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal disease characterized by irreversible scarring and progressive decline of lung function, with a median survival time of 2–3 years following diagnosis[1]. The pathogenesis underlying IPF is poorly understood. Increasing evidence suggests that it results from abnormal wound healing following repetitive alveolar injury, accompanied by chronic inflammation associated with various types of inflammatory cells[2,3]. Additional critical mechanisms associated with IPF progression are damage and apoptosis of alveolar epithelial cells and proliferation and differentiation of fibroblasts to secrete the extracellular matrix[4].

The interleukin (IL)-17 family is composed of six members, IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F, according to homology-based cloning analysis. To date, most IL-17 family members have been shown to be produced by numerous cell types; they participate in a wide range of inflammatory diseases, including asthma, pneumonitis, and pulmonary fibrosis[5]. These cytokines act on endothelial and epithelial mesenchymal lineages and immunocytes to induce the secretion of cytokines and chemokines, such as granulocyte macrophage-colony stimulating factor (GM-CSF), tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), IL-1 $\beta$ , and IL-18[6]; exert a key function in the migration and differentiation of neutrophils

in the lungs[7]; and contribute to airway remodeling by promoting the production of the profibrotic mediators IL-6 and IL-11 by fibroblasts[8-12]. The prototypical IL-17 family member IL-17A plays a key role in various inflammatory conditions by promoting the expression of inflammatory factors, including cytokines, chemokines, matrix metalloproteinases, and acute phase proteins. Overexpression or abnormal activity of IL-17A under pathological conditions can drive pulmonary fibrosis[13]. IL-17B is a less-characterized member of the IL-17 family. A recent study demonstrated that IL-17B induced the production of pro-inflammatory cytokines by inducing downstream signaling molecules through IL-17 receptor A (IL-17RA) and IL-17 receptor B (IL-17RB), which promote Th17 cell differentiation or neutrophil recruitment and activation to drive bleomycin (BLM)-induced pulmonary fibrosis progression. IL-17E has been demonstrated to play an analogous and crucial role in accelerating BLM-induced pulmonary fibrosis. IL-17C and IL-17D have been reported to play key roles in inflammatory pathologies, including lung inflammation; however, there is little direct evidence for their role in IPF[14,15]. In this review, we summarize the current knowledge regarding the biological functions of IL-17 family cytokines and their involvement in the pathogenesis and progression of IPF.

## Biological characteristics of IL-17 family cytokines

IL-17 was first identified in 1993[16,17], and in the following years, five other IL-17 family members, IL-17B, IL-17C,

\*Correspondence: gyan@stu.edu.cn

<sup>4</sup>Department of Radiology, the Second Affiliated Hospital of Xiamen Medical College, Xiamen 361000, Fujian, China


Full list of author information is available at the end of the article

IL-17D, IL-17E, and IL-17F, were gradually discovered using sequence homology analysis. The first discovered IL-17 is termed IL-17A[18]. The sequences of IL-17A and IL-17F show approximately 55% homology, and they are often co-expressed. IL-17B, IL-17C, and IL-17D share 23%–29% sequence homology, while IL-17E shares only 17% sequence identity with IL-17A, indicating that it is the most divergent subtype of the family[19,20]. The IL-17 family members are secreted as disulfide-linked homodimers, with a molecular weight of 17–21 kD.

The IL-17 cytokines exert their functions by activating their heterodimeric transmembrane receptors, which were first discovered in 1995[21]. This discovery led to the successive identification of other homologous subunits, which are now termed as a new class of receptors: the IL-17R family, which consists of IL-17RA, IL-17RB, IL-17RC, IL-17RD, and IL-17RE, with IL-17RA as a common receptor. IL-17A and IL-17F bind to a dimeric IL17RA/RC complex, IL-17B and IL-17E bind to a dimeric 17RA/RB complex, and IL-17C binds to the IL-17RA/RE complex[22,23]. However, the subunits of heterodimers specific to IL-17RD are yet to be

identified[24-26].

All receptor subunits are single transmembrane chains that contain an extracellular fibronectin (FN) III domain and share a cytoplasmic motif, similar expression to fibroblast growth factor (SEF)/IL-17R (SEFIR) remove[27], which is conserved within the IL-17R family and is similar to the Toll/IL-1R homologous region (TIR domain)[28]. The SEFIR domain transduces the related signal to activate the adaptor protein nuclear factor-kappaB (NF-κB) activator 1 (Act1), followed by E3 ligase activation and the recruitment and ubiquitination of tumor necrosis factor receptor-associated factor 6 (TRAF6)[23]. TRAF6 subsequently activates multiple signaling pathways, such as members of the CCAAT/enhancer-binding protein (C/EBP) family and mitogenactivated protein kinase (MAPK) pathway, including JUN N-terminal kinase (JNK), extracellular signal-regulated kinase (ERK), and p38 MAPK, leading to the activation of NF-κB. In the nucleus, NF-κB induces the transcription of target genes directly or in combination with other transcription factors such as activator protein-1 (AP-1) (Fig. 1)[29-31].



**Fig. 1 IL-17 cytokines, receptors, and signaling.**

The IL-17 family is composed of six members, IL-17A – F, while the IL-17 receptor family is composed of five members, IL-17RA to IL-17RE (IL-17RD not shown). IL-17 signaling is activated through the binding of the IL-17 receptor complex to the adaptor protein Act1, which has been determined in IL-17C to recruit TRAF6 to drive the activation of downstream signaling pathways, MAPK, C/EBP, and NF-κB, contributing to the target gene expression as well as mediating the host defense and inflammatory response. IL-17R. Interleukin 17 receptor; TRAF6. Tumor necrosis factor receptor-associated factor 6; C/EBP. CCAAT/enhancer-binding protein; MAPK. Mitogen-activated protein kinase; NF-κB. Nuclear factor-kappaB; Act1. NF-κB activator 1; JNK. JUN N-terminal kinase; ERK. Extracellular signal-regulated kinase; FN. Fibronectin; AP1. Activator protein-1

## Pro-inflammatory function of IL-17A and IL-17F in pulmonary fibrosis

### IL-17A

IL-17A, the prototypic subtype of the IL-17 family, was first discovered in 1993 and named CTLA8 [32]. It was subsequently renamed IL-17 and, more recently, IL-17A.

IL-17A can be secreted by multiple cell types, including Th17, CD8<sup>+</sup> T (Tc17),  $\gamma\delta$  T17, innate immune, and non-hematopoietic cells. It exerts its considerable influence *via* binding to the IL17RA/IL17RC heterodimer[22]. IL-17A production was reported to be significantly elevated in the bronchoalveolar lavage fluid of patients with IPF[33]. In IPF tissues, elevated IL-17 production can be observed in areas of active disease[34-36]. In these regions, IL-17 was originally reported to be mainly secreted by Th17 lymphocytes but was subsequently demonstrated to be produced by regenerating epithelium cells as well as immune cells, including  $\gamma\delta$  T cells, neutrophils, macrophages, and NK T cells[37]. IPF has been linked to repetitive epithelial cell injury, chronic inflammatory response, and activation of fibroblasts to secrete the extracellular matrix[38]. IL-17A is pivotal for multiple critical processes that promote fibrosis, including tissue repair, inflammatory response, and epithelial-mesenchymal transition (EMT)[39].

Multiple animal modeling studies have explored the role of IL-17A in driving early lung inflammation and fibrosis. During BLM injury, IL-17A expression is upregulated, contributing to the increased expression of other pro-inflammatory cytokines, including TNF- $\alpha$ , IL-1, IL-6, and TGF- $\beta$ , as well as chemokines, such as IL-8, C-C motif chemokine (CCL) 2, C-X-C motif chemokine (CXCL) 1, and CXCL5, by endothelial cells and epithelial cells[40-42]. These molecules recruit certain inflammatory cells to the alveolar surface, and subsequent inflammation promotes pulmonary fibrosis[43]. Several studies have shown that BLM-stimulated IL-17 triggered significant neutrophilia and a marked increase in the levels of pro-inflammatory cytokines, such as IL-6 and IL-1 $\beta$ , and promoted pulmonary fibrosis[44]. Thus, IL-17A blockade by intraperitoneal anti-IL-17A alleviates the acute inflammatory and fibrotic features in mice[43]. Some studies have demonstrated that depletion of alveolar macrophages downregulates IL-17 responses to silica-induced early alveolitis and fibrosis by mediating the production of IL-23 and IL-1 $\beta$ [45].


IL-17A and its signaling cascade IL-17R subunits, as well as the post-translational modification of Act1, mediate tissue inflammation through various signaling pathways[44]. However, the receptor for IL-17A is also ubiquitously

expressed in non-hematopoietic cells, including epithelial cells and fibroblasts, which play a vital role in the development of pulmonary fibrosis by EMT and differentiation into myofibroblasts, resulting in enhanced extracellular matrix deposition[46]. Additionally, IL-17 can play a role in lung fibrosis by suppressing autophagy in epithelial cells[47]. Consistent with this effect, IL-17A neutralization promoted autophagy, which presumably favored collagen resolution in the lungs[48]. In addition, in some studies, IL-17R production has been found to be elevated in fibroblasts following BLM challenge, and administration of exogenous IL-17 can accelerate fibroblast proliferation, leading to increased expression of  $\alpha$ -smooth muscle actin ( $\alpha$ -SMA) and collagen[49]. Mechanically, IL-17 stimulation of fibroblasts occurs *via* activation of the NF- $\kappa$ B/Act1 signaling pathway[50,51].

### IL-17F

IL-17F shares the highest sequence homology (55%) and overlapping biological function with IL-17A[52], and the cell sources of IL-17F are similar to IL-17A, including Th17 cells,  $\gamma\delta$  T cells, CD8<sup>+</sup> T cells (Tc17), and innate lymphoid cells. Additionally, IL-17F signaling occurs through the same IL-17RA/RC receptor complex. Thus, IL-17F expression is upregulated in multiple inflamed human tissues, and the importance of IL-17F in autoimmune and inflammatory diseases is becoming increasingly apparent[52,53]. By inducing various cytokines, such as IL-6, and CXC chemokines in human tracheal epithelial cells, vein endothelial cells, inflammatory cells, and fibroblasts, IL-17F plays vital roles in allergic and chronic inflammatory lung disease[54]. Previous research has shown that IL-17F induces similar pathological phenotypes, such as recruitment of neutrophils and the same downstream inflammatory genes *via* the signaling components of IL-17RA, Act1, and TRAF6, which have been identified as key players in the IL-17A-mediated inflammatory response[55]. In addition, specific overexpression of IL-17F in the lungs of mice leads to infiltration of macrophages and lymphocytes as well as mucus production[52]. Currently, there is no direct evidence for the contribution of IL-17F to the progression of IPF; however, these observations related to IL-17A and inflammatory responses suggest that IL-17F may be an effective target for the treatment of IPF.

In summary, IL-17A derived from various cell types plays an important role in controlling the inflammatory response and fibrosis progression in IPF, and IL-17F may exert similar anti-inflammatory and anti-fibrotic effects, which need to be further explored (Fig. 2).



## Pro-inflammatory function of IL-17B and IL-17D in pulmonary fibrosis

### IL-17B

IL-17B was initially identified using a homology-based expressed sequence tag (EST) database[56,57]. PCR and Northern blot analysis showed that IL-17B expression was strong in the heart, testis tissues, and brain of mice, which have approximately 87.8% similarity to humans, and relatively low in other tissues, including in the liver, lungs, and skeletal muscle tissues[57]. IL-17B is functionally similar to IL-25 and elicits type 2 cytokine secretion from innate type 2 lymphocytes, NKT, and CD4<sup>+</sup> CRTH2<sup>+</sup> Th2 cells. Some reports revealed that this activity of IL-17B was dependent on the IL-17RA

and IL-17RB receptor subunits[58]; however, it was shown to display a weak affinity of 7.6 nmol/L between IL-17B and IL-17RB[57].

Research on IL-17B has been limited. Recent studies have shown that the epithelium weakly expresses IL-17B, whereas some connective tissue cells express abundant IL-17B, and neutrophils significantly express IL-17B[59]. Moreover, considerable amounts of IL-17B protein have been detected in naive and memory B cells, germinal center (GC) B cells, and neuronal cells.

The function of IL-17B has not been thoroughly investigated, but several studies have revealed that its function partially overlaps with that of IL-17A and that it exhibits


pro-inflammatory effects under certain conditions[60]. For example, IL-17B increases the production of the inflammatory mediators IL-6, IL-23, and IL-1 $\alpha$  in the peritoneal exudate cells and 3T3 cell line[61] as well as the production of TNF- $\alpha$  and IL-1 $\beta$  in THP-1 cells, a cell line derived from human monocyte/macrophage cells[56]. IL-17B promotes the recruitment of C-X-C chemokine receptor (CXCR) $^4$  or CXCR5 $^+$  GC B cells to CXCL12 and CXCL13, and intraperitoneal administration of recombinant human IL-17B causes the migration of neutrophils to the peritoneal cavity and triggers the secretion of chemoattractive factors from multiple cell types[57]. Additionally, IL-17B can enhance IL-33-driven type 2 immune responses[62]. These pro-inflammatory functions suggest that IL-17B may influence the progression of IPF, which is prompted by early inflammation of the lung. However, no direct study identified this until Yang *et al.*[63] reported in 2019 that the expression of IL-17B was induced by dysregulated microbiota and that it induced lung fibrosis in a BLM-induced mouse model by interacting with TNF- $\alpha$  to stimulate the secretion of Th17-cell-promoting genes and neutrophil-recruiting genes (Fig. 3). Further studies are required to determine the detailed mechanism of action of IL-17B in cellular and IPF models.

#### IL-17D

The IL-17D isoform of the IL-17 family, which maps to chromosome 13p11 in humans, discovered in 2002 displays 27% sequence identity with IL-17B[15]. The receptors and functions of IL-17D remain poorly understood. IL-17D mRNA is observed in a wide range of tissues, including the adipose tissue, lung, heart, pancreas, and brain. Intriguingly, IL-17D is detected only in B cells and resting CD4 $^+$  T cells among activated immune cells and rarely stimulates immune cells; it contributes to the secretion of pro-inflammatory factors through endothelial cells[64]. Knowledge of IL-17D in the regulation of pulmonary fibrosis remains limited, and further investigations are needed to understand the relationship between IL-17D-induced inflammatory response and pulmonary fibrosis development.

#### Effect of IL-17C in pulmonary fibrosis from its various inflammatory function

IL-17C was first discovered by Li *et al.*[56] and exhibited low sequence homology (23%) with IL-17A. IL-17C has been shown to be expressed in various cells, including epithelial cells, CD4 $^+$  T cells, DCs, and macrophages. IL-17C produced by epithelial cells has been reported to be associated with antimicrobial activity[65]. Stimulation of respiratory epithelial cells with whole bacteria *in vitro* and bacterial challenge in a



**Fig. 3 Main cellular sources and targets of IL-17B in IPF.**

IL-17B is mainly secreted from the epithelium, neutrophils, and B cells. It plays an important role in mediating lung inflammation by stimulating the expression of the inflammatory mediators IL-6, IL-23, TNF- $\alpha$ , IL-1 $\beta$ , and chemokines from macrophages, neutrophils, and Th17 cells. IL-17B induces lung fibrosis by cooperating with TNF- $\alpha$  to stimulate the secretion of Th17-cell-promoting genes and neutrophil-recruiting genes. Th17. T helper cell 17; TNF- $\alpha$ . Tumor necrosis factor- $\alpha$ ; IL-1 $\beta$ . Interleukin-1 $\beta$ ; CXCL12. C-X-C motif chemokine ligand 12; CXCL13. C-X-C motif chemokine ligand 13; IPF. Idiopathic pulmonary fibrosis

mouse model rapidly induced IL-17C expression[66], leading to an enhanced lung inflammatory response[67].

Several studies have shown that IL-17C acts through an IL-17 receptor complex, consisting of the common IL-17RA subunit, which is shared with IL-17A, IL-17F, and IL-17B, and the specific IL-17RE subunit[23,68]. IL-17RE has been shown to be located mainly on epithelial cells and Th17 cells. Th17 cells can produce elevated amounts of IL-17A, IL-17F, and IL-22 stimulated by IL-17C, indicating that IL-17C might promote cell differentiation or maintenance[68]. Additionally, IL-17RA and IL-17RE have been reported to be expressed on other types of cells; they enable IL-17C to play an important role in host defense, autoimmune, and inflammatory pathologies including lung inflammation[62,63]. For example, adoptive transfer of IL-17C-transduced CD4 $^+$  T cells leads to significantly exacerbated collagen-induced arthritis[68]; IL-17C induces the release of TNF- $\alpha$  and IL-1 $\beta$  from THP-1,


a monocytic cell line[61]; and adenoviral challenge of IL-17C in the lung triggers neutrophil recruitment[69].

A specific NF- $\kappa$ B binding site has been identified in the promoter region of IL-17C, and IL-17C production is dependent on NF- $\kappa$ B activation. Intriguingly, IL-17C binds to its receptor subunits IL-17RA and IL-17RE, activating the Act1 complex, which in turn activates the NF- $\kappa$ B and MAPK signaling molecules, contributing to the secretion of inflammatory factors and lung destruction[70].

The function of the IL-17C isoform in the progression of IPF has not been extensively investigated, and pulmonary fibrosis has been widely demonstrated to be driven by epithelial cell injury and the inflammatory response during wound healing, which is associated with the function of multiple immunocytes[71,72]. Early lipopolysaccharide-induced lung injury can be established as a model of pulmonary fibrosis. Reports of related injury of epithelial cells, release of pro-inflammatory mediators, and IL-17C-induced neutrophil recruitment identified its important roles in lung inflammation. Boosted IL-17 production of IL-17C in IL-33-, NTHi- and cigarette smoke-induced lung inflammation has been recently reported[73,74]. All of these findings suggest that IL-17C might be a key cytokine in the pathogenesis of pulmonary fibrosis (Fig. 4). Nevertheless, definitive evidence is yet to be provided, and the underlying mechanisms of action of IL-17C in regulating pulmonary fibrosis remain to be elucidated.

### Protective and promotive roles of IL-17E in inflammatory response and fibrosis in lungs

IL-17E, commonly known as IL-25, was originally discovered in Th2 cells in 2001 and later classified as an isoform of the IL-17 family. Later, scientists observed that IL-17E is secreted not only by Th2 cells but also by epithelial cells, endothelial cells, T cells, alveolar macrophages, ILC2s, DCs, eosinophils, and basophils, all of which are associated with inflammatory responses[75,76]. IL-17E signals through a heterodimeric receptor composed of IL-17RA and IL-17RB, both of which are essential for cytokine expression in target cells during inflammatory disorders. IL-17E initiates allergic airway diseases by producing excessive cytokines, such as IL-4, IL-5, and IL-13[77]. Remarkably, IL-17E plays protective role in some inflammatory responses, such as parasitic infection and dextran sulfate sodium-induced colitis[78,79]. A few recent studies have revealed that IL-17 is involved in the development of lung fibrosis. Xu *et al.*[80] reported augmented levels of IL-17E (IL-25) and its receptor IL-17RB in the lung tissues of patients with IPF and showed that they drove lung fibrosis




**Fig. 4 Main cellular sources and targets of IL-17C in lung inflammatory response.**

IL-17C is expressed in various cells, including epithelial cells, Th17 cells, CD4<sup>+</sup> T cells, DCs, and macrophages. It acts on multiple types of cells, including CD4<sup>+</sup> T cells, macrophages, and neutrophils, playing an important role in lung inflammation. Definitive evidence has not been reported for the role of IL-17C in regulating pulmonary fibrosis. Th17. T helper cell 17; TNF- $\alpha$ . Tumor necrosis factor- $\alpha$ ; IL-1 $\beta$ . Interleukin-1 $\beta$ ; IPF. Idiopathic pulmonary fibrosis

by mediating the EMT of alveolar epithelial cells as well as recruiting and activating lung fibroblasts. Hams *et al.*[81] observed a population of type 2 innate lymphoid cells (ILC2s) and increased production of IL-25 in the lungs of patients with IPF and reported that IL-25 promoted the release of IL-13 from ILC2s, which triggered collagen deposition during the IPF process. The relationship between IL-17E and IPF is summarized in Fig. 5. Further investigation is required for identifying other mechanisms by which IL-25 regulates IPF.

### Conclusions

The potential role of IL-17 isoforms in pulmonary fibrosis has attracted increasing interest over the last few years. Several members of the IL-17 family have been identified to be promptly secreted by either immune cells or non-hematopoietic cells, playing vital roles *via* cascade signaling in key stages of IPF progression from the early inflammatory response to the late fibrotic process. Other undefined isoforms have been implicated in mediating protection against antimicrobial infections and inflammatory responses (Table 1). The current challenge is to precisely define the interplay



**Table 1 Preclinical and clinical data of IL-17 family members in pulmonary inflammation and fibrosis**

IL-17 family member	Expression changes in inflammatory lung	Preclinical role in PF	Clinical role in PF
IL-17A	Elevated in BLM, IL-33 and LPS-induced lung inflammation[36,44]	Contributing to fibrosis by promoting proinflammatory cytokines[39,43]; triggering neutrophilia[44]; promoting EMT[46], accelerating fibroblasts proliferation, differentiation[46,49]	Elevated in: lung of RA-ILD patients[35]; airways of cystic fibrosis patients[34]
IL-17B	Expression of IL-17B was induced by dysregulated microbiota[63]	Elevated in BLM-induced PF mouse model by regulating Th17-cell-promoting genes and neutrophil-recruiting genes[63]	No data
IL-17C	IL-17C contributes to NTHi-induced inflammation and lung damage[74]	Remains limited	No data
IL-17D	Remains limited	Remains limited	No data
IL-17E	Protective roles in inflammatory response[75,76]	Drove lung fibrosis by mediating EMT; recruiting and activating lung fibroblasts[80]; promotes IL-13 from ILC2s; triggering collagen deposition[81]	Elevated in lung of IPF patients[80]
IL-17F	Recruitment of neutrophils, macrophages, lymphocytes; promotes inflammatory cytokines[52,55]	No direct evidence for the progression of IPF	

IL-17. Interleukin 17; IPF. Idiopathic pulmonary fibrosis; BLM. Bleomycin; IL-33. Interleukin-33; LPS. Lipopolysaccharides; NTHi. Nontypeable Haemophilus influenzae; PF. Pulmonary fibrosis; EMT. Epithelial-mesenchymal transition; Th17 cells. T helper cell 17; IL-13. Interleukin-13; ILC2s. Group II innate lymphoid cells; RA. Rheumatoid arthritis; ILD. Interstitial lung disease

among these IL-17 isoforms and determine their mechanisms of action in the pathogenesis of IPF.

Drugs that target IL-17 signaling are presently available in the market; brodalumab inhibits the human IL-17A receptor, and secukinumab and ixekizumab block IL-17A itself[82,83]. These three FDA-approved IL-17 inhibitors have demonstrated marked efficacy in patients with inflammatory diseases, such as ankylosing spondylitis and psoriatic arthritis[83-85]. Through

additional preclinical data and clinical trials that explore the efficacy of IL-17 neutralization for IPF, the usefulness of IL-17-related monoclonal antibodies in IPF should be considered. Furthermore, extensive information on the precise signaling mechanisms and biological functions of each IL-17 member would pave the way for therapeutic interventions that selectively target specific IL-17 members for the treatment of IPF in humans.

## Abbreviations

AP-1: Activator protein-1; BLM: Bleomycin; C/EBP: CCAAT/enhancer-binding protein; CXCR: C-X-C chemokine receptor; EMT: Epithelial-mesenchymal transition; ERK: Extracellular signal-regulated kinase; EST: Expressed sequence tag; FN: Fibronectin; GC: Germinal center; GM-CSF: Granulocyte macrophage colony stimulating factor; IL: Interleukin; IL-17R: IL-17 receptor; ILC-2: Type 2 innate lymphoid cells; IPF: Idiopathic pulmonary fibrosis; JNK: JUN N-terminal kinase; LPS: Lipopolysaccharide; MAPK: Mitogen-activated protein kinase; NF- $\kappa$ B: Nuclear factor  $\kappa$ B; SEF: Similar expression to fibroblast growth factor; SEFIR: SEF/IL-17R;  $\alpha$ -SMA:  $\alpha$ -smooth muscle actin; TNF- $\alpha$ : Tumor necrosis factor- $\alpha$ ; TRAF-6: Tumor necrosis factor receptor-associated factor 6.

## Acknowledgements

None.

## Authors' contributions

YJN and GY organized and executed the research projects. YJN, YHX, and SHW wrote and reviewed the manuscript. All of the above authors contributed to this article and approved the final submitted version. All authors read and approved the final manuscript.

## Funding

This research was supported by the Natural Science Foundation of Jiangsu Province (BK20180616), the Joint Funds for the Health and Education of Fujian Province (2019-WJ-31), and the Institute of Respiratory Diseases, Xiamen Medical College (HXJB-15).

## Availability of data and materials

Not applicable.

## Declarations

### Ethics approval and consent to participate

Not applicable.

### Consent for publication

Not applicable.

## Competing interests

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Author details

<sup>1</sup>Department of Basic Medicine, Wuxi School of Medicine, Jiangnan University, Wuxi 214000, Jiangsu, China. <sup>2</sup>Department of Radiology, the Second Affiliated Hospital, Medical College of Shantou University, Shantou 515000, Guangdong, China. <sup>3</sup>Department of Basic Medicine, Xiamen Medical College, Xiamen 361000, Fujian, China. <sup>4</sup>Department of Radiology, the Second Affiliated Hospital of Xiamen Medical College, Xiamen 361000, Fujian, China.

## References

1. Barratt SL, Creamer A, Hayton C, Chaudhuri N. Idiopathic pulmonary fibrosis (IPF): an overview. *J Clin Med*. 2018;7(8):201.
2. Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, et al. Idiopathic pulmonary fibrosis. *Nat Rev Dis Primers*. 2017;3:17074.

3. Chanda D, Otoupalova E, Smith SR, Volckaert T, De Langhe SP, Thannickal VJ. Developmental pathways in the pathogenesis of lung fibrosis. *Mol Aspects Med*. 2019;65:56–69.
4. Lee JM, Yoshida M, Kim MS, Lee JH, Baek AR, Jang AS, et al. Involvement of alveolar epithelial cell necroptosis in idiopathic pulmonary fibrosis pathogenesis. *Am J Respir Cell Mol Biol*. 2018;59(2):215–24.
5. Song X, Qian Y. IL-17 family cytokines mediated signaling in the pathogenesis of inflammatory diseases. *Cell Signal*. 2013;25(12):2335–47.
6. Ito Y, Correll K, Zemans RL, Leslie CC, Murphy RC, Mason RJ. Influenza induces IL-8 and GM-CSF secretion by human alveolar epithelial cells through HGF/c-Met and TGF- $\alpha$ /EGFR signaling. *Am J Physiol Lung Cell Mol Physiol*. 2015;308(11):L1178–88.
7. Aulakh GK. Neutrophils in the lung: “the first responders.” *Cell Tissue Res*. 2018;371(3):577–88.
8. Pelaia G, Gallelli L, D’agostino B, Vatrella A, Cuda G, Fratto D, et al. Effects of TGF- $\beta$  and glucocorticoids on map kinase phosphorylation, IL-6/IL-11 secretion and cell proliferation in primary cultures of human lung fibroblasts. *J Cell Physiol*. 2007;210(2):489–97.
9. Cook SA, Schafer S. Hiding in plain sight: interleukin-11 emerges as a master regulator of fibrosis, tissue integrity, and stromal inflammation. *Annu Rev Med*. 2020;71:263–76.
10. Montero P, Milara J, Roger I, Cortijo J. Role of JAK/STAT in interstitial lung diseases; molecular and cellular mechanisms. *Int J Mol Sci*. 2021;22(12):6211.
11. Prele CM, Yao E, O’donoghue RJ, Mutsaers SE, Knight DA. STAT3: a central mediator of pulmonary fibrosis? *Proc Am Thorac Soc*. 2012;9(3):177–82.
12. Jaffar J, Mcmillan L, Wilson N, Panousis C, Hardy C, Cho HJ, et al. Coagulation Factor-XII induces interleukin-6 by primary lung fibroblasts: a role in idiopathic pulmonary fibrosis? *Am J Physiol Lung Cell Mol Physiol*. 2021;322(2):L258–72.
13. Celada LJ, Kropski JA, Herazo-Maya JD, Luo W, Creecy A, Abad AT, et al. PD-1 up-regulation on CD4<sup>+</sup> T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF- $\beta$ 1 production. *Sci Transl Med*. 2018;10(460):eaar8356.
14. Yamaguchi S, Nambu A, Numata T, Yoshizaki T, Narushima S, Shimura E, et al. The roles of IL-17C in T cell-dependent and -independent inflammatory diseases. *Sci Rep*. 2018;8(1):15750.
15. Starnes T, Broxmeyer HE, Robertson MJ, Hromas R. Cutting edge: IL-17D, a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis. *J Immunol*. 2002;169(2):642–6.
16. Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff BM, Spriggs MK, et al. Human IL-17: a novel cytokine derived from T cells. *J Immunol*. 1995;155(12):5483–6.
17. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. *J Exp Med*. 1996;183(6):2593–603.
18. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. *Annu Rev Immunol*. 2009;27:485–517.
19. Ding Y, Ao J, Ai C, Chen X. Molecular and functional identification of three interleukin-17A/F (IL-17A/F) homologues in large yellow croaker (*Larimichthys crocea*). *Dev Comp Immunol*. 2016;55:221–32.
20. Kolls JK, Linden A. Interleukin-17 family members and

- inflammation. *Immunity*. 2004;21(4):467–76.
21. Yao Z, Fanslow WC, Seldin MF, Rousseau AM, Painter SL, Comeau MR, *et al.* Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. *Immunity*. 1995;3(6):811–21.
  22. Gaffen SL. Structure and signalling in the IL-17 receptor family. *Nat Rev Immunol*. 2009;9(8):556–67.
  23. McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 family of cytokines in health and disease. *Immunity*. 2019;50(4):892–906.
  24. Ramirez-Carrozzi V, Sambandam A, Luis E, Lin Z, Jeet S, Lesch J, *et al.* IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. *Nat Immunol*. 2011;12(12):1159–66.
  25. Rickel EA, Siegel LA, Yoon BR, Rottman JB, Kugler DG, Swart DA, *et al.* Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities. *J Immunol*. 2008;181(6):4299–310.
  26. Toy D, Kugler D, Wolfson M, Vanden Bos T, Gurgel J, Derry J, *et al.* Cutting edge: interleukin 17 signals through a heteromeric receptor complex. *J Immunol*. 2006;177(1):36–9.
  27. Yang H, Zhu Y, Chen X, Li X, Ye S, Zhang R. Structure of a prokaryotic SEFIR domain reveals two novel SEFIR-SEFIR interaction modes. *J Struct Biol*. 2018;203(2):81–9.
  28. Ely LK, Fischer S, Garcia KC. Structural basis of receptor sharing by interleukin 17 cytokines. *Nat Immunol*. 2009;10(12):1245–51.
  29. Hadian Y, Bagood MD, Dahle SE, Sood A, Isseroff RR. Interleukin-17: potential target for chronic wounds. *Mediators Inflamm*. 2019;2019:1297675.
  30. Qian Y, Liu C, Hartupee J, Altuntas CZ, Gulen MF, Jane-Wit D, *et al.* The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. *Nat Immunol*. 2007;8(3):247–56.
  31. Schwandner R, Yamaguchi K, Cao Z. Requirement of tumor necrosis factor receptor-associated factor (TRAF)6 in interleukin 17 signal transduction. *J Exp Med*. 2000;191(7):1233–40.
  32. Rouvier E, Luciani MF, Mattei MG, Denizot F, Golstein P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. *J Immunol*. 1993;150(12):5445–56.
  33. Tiringer K, Treis A, Fucik P, Gona M, Gruber S, Renner S, *et al.* A Th17- and Th2-skewed cytokine profile in cystic fibrosis lungs represents a potential risk factor for *Pseudomonas aeruginosa* infection. *Am J Respir Crit Care Med*. 2013;187(6):621–9.
  34. Brodlie M, Corris PA, Lordan J, Ward C. Interleukin-17 and cystic fibrosis lung disease. *Am J Respir Crit Care Med*. 2012;185(1):108–9.
  35. Zhang J, Wang D, Wang L, Wang S, Roden AC, Zhao H, *et al.* Profibrotic effect of IL-17A and elevated IL-17RA in idiopathic pulmonary fibrosis and rheumatoid arthritis-associated lung disease support a direct role for IL-17A/IL-17RA in human fibrotic interstitial lung disease. *Am J Physiol Lung Cell Mol Physiol*. 2019;316(3):L487–97.
  36. Li D, Guabiraba R, Besnard AG, Komai-Koma M, Jabir MS, Zhang L, *et al.* IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice. *J Allergy Clin Immunol*. 2014;134(6):1422–32. e11.
  37. Kono M, Miyashita K, Hiram R, Oshima Y, Takeda K, Mochizuka Y, *et al.* Prognostic significance of bronchoalveolar lavage cellular analysis in patients with acute exacerbation of interstitial lung disease. *Respir Med*. 2021;186:106534.
  38. Chambers RC, Mercer PF. Mechanisms of alveolar epithelial injury, repair, and fibrosis. *Ann Am Thorac Soc*. 2015;12(Suppl 1):S16–20.
  39. Shaikh SB, Prabhu A, Bhandary YP. Interleukin-17A: a potential therapeutic target in chronic lung diseases. *Endocr Metab Immune Disord Drug Targets*. 2019;19(7):921–8.
  40. Albanesi C, Cavani A, Girolomoni G. IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN $\gamma$  and TNF- $\alpha$ . *J Immunol*. 1999;162(1):494–502.
  41. Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. *Immunity*. 2011;34(2):149–62.
  42. Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, *et al.* IL-17 stimulates the production and expression of proinflammatory cytokines, IL- $\beta$  and TNF- $\alpha$ , by human macrophages. *J Immunol*. 1998;160(7):3513–21.
  43. Gouda MM, Bhandary YP. Acute lung injury: IL-17A-mediated inflammatory pathway and its regulation by curcumin. *Inflammation*. 2019;42(4):1160–9.
  44. Wilson MS, Madala SK, Ramalingam TR, Gochoico BR, Rosas IO, Cheever AW, *et al.* Bleomycin and IL-1 $\beta$ -mediated pulmonary fibrosis is IL-17A dependent. *J Exp Med*. 2010;207(3):535–52.
  45. Golebski K, Ros XR, Nagasawa M, Van Tol S, Heesters BA, Aglmous H, *et al.* IL-1 $\beta$ , IL-23, and TGF- $\beta$  drive plasticity of human ILC2s towards IL-17-producing ILCs in nasal inflammation. *Nat Commun*. 2019;10(1):2162.
  46. Wang T, Liu Y, Zou JF, Cheng ZS. Interleukin-17 induces human alveolar epithelial to mesenchymal cell transition *via* the TGF- $\beta$ 1 mediated Smad2/3 and ERK1/2 activation. *PLoS One*. 2017;12(9):e0183972.
  47. Cipolla E, Fisher AJ, Gu H, Mickler EA, Agarwal M, Wilke CA, *et al.* IL-17A deficiency mitigates bleomycin-induced complement activation during lung fibrosis. *FASEB J*. 2017;31(12):5543–56.
  48. Liu H, Mi S, Li Z, Hua F, Hu ZW. Interleukin 17A inhibits autophagy through activation of PIK3CA to interrupt the GSK3B-mediated degradation of BCL2 in lung epithelial cells. *Autophagy*. 2013;9(5):730–42.
  49. Chrysanthopoulou A, Mitroulis I, Apostolidou E, Arelaki S, Mikroulis D, Konstantinidis T, *et al.* Neutrophil extracellular traps promote differentiation and function of fibroblasts. *J Pathol*. 2014;233(3):294–307.
  50. Heo YJ, Oh HJ, Jung YO, Cho ML, Lee SY, Yu JG, *et al.* The expression of the receptor for advanced glycation end-products (RAGE) in RA-FLS is induced by IL-17 *via* Act-1. *Arthritis Res Ther*. 2011;13(4):R113.
  51. Wei L, Liu M, Xiong H, Peng B. Up-regulation of IL-23 expression in human dental pulp fibroblasts by IL-17 *via* activation of the NF- $\kappa$ B and MAPK pathways. *Int Endod J*. 2018;51(6):622–31.
  52. Yang XO, Chang SH, Park H, Nurieva R, Shah B, Acero L, *et al.* Regulation of inflammatory responses by IL-17F. *J Exp Med*. 2008;205(5):1063–75.
  53. Hot A, Miossec P. Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes. *Ann Rheum Dis*. 2011;70(5):727–32.
  54. Glatt S, Baeten D, Baker T, Griffiths M, Ionescu L, Lawson ADG, *et al.* Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. *Ann Rheum Dis*. 2018;77(4):523–32.

55. Chang SH, Dong C. IL-17F: regulation, signaling and function in inflammation. *Cytokine*. 2009;46(1):7–11.
56. Li H, Chen J, Huang A, Stinson J, Heldens S, Foster J, et al. Cloning and characterization of IL-17B and IL-17C, two new members of the IL-17 cytokine family. *Proc Natl Acad Sci U S A*. 2000;97(2):773–8.
57. Shi Y, Ullrich SJ, Zhang J, Connolly K, Grzegorzewski KJ, Barber MC, et al. A novel cytokine receptor-ligand pair. Identification, molecular characterization, and *in vivo* immunomodulatory activity. *J Biol Chem*. 2000;275(25):19167–76.
58. Ramirez-Carrozzi V, Ota N, Sambandam A, Wong K, Hackney J, Martinez-Martin N, et al. Cutting edge: IL-17B uses IL-17RA and IL-17RB to induce Type 2 inflammation from human lymphocytes. *J Immunol*. 2019;202(7):1935–41.
59. Kouri VP, Olkkonen J, Ainola M, Li TF, Bjorkman L, Kontinen YT, et al. Neutrophils produce interleukin-17B in rheumatoid synovial tissue. *Rheumatology (Oxford)*. 2014;53(1):39–47.
60. Reynolds JM, Lee YH, Shi Y, Wang X, Angkasekwinai P, Nallaparaju KC, et al. Interleukin-17B antagonizes interleukin-25-mediated mucosal inflammation. *Immunity*. 2015;42(4):692–703.
61. Yamaguchi Y, Fujio K, Shoda H, Okamoto A, Tsuno NH, Takahashi K, et al. IL-17B and IL-17C are associated with TNF-alpha production and contribute to the exacerbation of inflammatory arthritis. *J Immunol*. 2007;179(10):7128–36.
62. Macgregor CH. Biosynthesis of membrane-bound nitrate reductase in *Escherichia coli*: evidence for a soluble precursor. *J Bacteriol*. 1976;126(1):122–31.
63. Yang D, Chen X, Wang J, Lou Q, Lou Y, Li L, et al. Dysregulated lung commensal bacteria drive interleukin-17B production to promote pulmonary fibrosis through their outer membrane vesicles. *Immunity*. 2019;50(3):692–706. e7.
64. Shabgah AG, Fattahi E, Shahneh FZ. Interleukin-17 in human inflammatory diseases. *Postepy Dermatol Alergol*. 2014;31(4):256–61.
65. Larocque-De-Freitas IF, Rocha JDB, Nunes MP, Oliveira PV, Nascimento DO, Freire-De-Lima L, et al. Involvement of the capsular GalXM-induced IL-17 cytokine in the control of *Cryptococcus neoformans* infection. *Sci Rep*. 2018;8(1):16378.
66. Wonnenberg B, Jungnickel C, Honecker A, Wolf L, Voss M, Bischoff M, et al. IL-17A attracts inflammatory cells in murine lung infection with *P. aeruginosa*. *Innate Immun*. 2016;22(8):620–5.
67. Wolf L, Sapich S, Honecker A, Jungnickel C, Seiler F, Bischoff M, et al. IL-17A-mediated expression of epithelial IL-17C promotes inflammation during acute *Pseudomonas aeruginosa* pneumonia. *Am J Physiol Lung Cell Mol Physiol*. 2016;311(5):L1015–22.
68. Chang SH, Reynolds JM, Pappu BP, Chen G, Martinez GJ, Dong C. Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E. *Immunity*. 2011;35(4):611–21.
69. Hurst SD, Muchamuel T, Gorman DM, Gilbert JM, Clifford T, Kwan S, et al. New IL-17 family members promote Th1 or Th2 responses in the lung: *in vivo* function of the novel cytokine IL-25. *J Immunol*. 2002;169(1):443–53.
70. Conti HR, Whibley N, Coleman BM, Garg AV, Jaycox JR, Gaffen SL. Signaling through IL-17C/IL-17RE is dispensable for immunity to systemic, oral and cutaneous candidiasis. *PLoS One*. 2015;10(4):e0122807.
71. Wynn TA. Integrating mechanisms of pulmonary fibrosis. *J Exp Med*. 2011;208(7):1339–50.
72. Weiskirchen R, Weiskirchen S, Tacke F. Organ and tissue fibrosis: molecular signals, cellular mechanisms and translational implications. *Mol Aspects Med*. 2019;65:2–15.
73. Cai T, Qiu J, Ji Y, Li W, Ding Z, Suo C, et al. IL-17-producing ST2(+) group 2 innate lymphoid cells play a pathogenic role in lung inflammation. *J Allergy Clin Immunol*. 2019;143(1):229–44. e9.
74. Vella G, Ritzmann F, Wolf L, Kamyschnikov A, Stodden H, Herr C, et al. IL-17C contributes to NTHi-induced inflammation and lung damage in experimental COPD and is present in sputum during acute exacerbations. *PLoS One*. 2021;16(1):e0243484.
75. Angkasekwinai P, Park H, Wang YH, Wang YH, Chang SH, Corry DB, et al. Interleukin 25 promotes the initiation of proallergic type 2 responses. *J Exp Med*. 2007;204(7):1509–17.
76. Xu M, Dong C. IL-25 in allergic inflammation. *Immunol Rev*. 2017;278(1):185–91.
77. Tamachi T, Maezawa Y, Ikeda K, Kagami S, Hatano M, Seto Y, et al. IL-25 enhances allergic airway inflammation by amplifying a TH2 cell-dependent pathway in mice. *J Allergy Clin Immunol*. 2006;118(3):606–14.
78. Saenz SA, Siracusa MC, Perrigoue JG, Spencer SP, Urban JF Jr, Tocker JE, et al. IL25 elicits a multipotent progenitor cell population that promotes T(H)2 cytokine responses. *Nature*. 2010;464(7293):1362–6.
79. Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. *Nature*. 2010;464(7293):1367–70.
80. Xu X, Luo S, Li B, Dai H, Zhang J. Feature Article: IL-25 contributes to lung fibrosis by directly acting on alveolar epithelial cells and fibroblasts. *Exp Biol Med (Maywood)*. 2019;244(9):770–80.
81. Hams E, Armstrong ME, Barlow JL, Saunders SP, Schwartz C, Cooke G, et al. IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis. *Proc Natl Acad Sci U S A*. 2014;111(1):367–72.
82. Campa M, Mansouri B, Warren R, Menter A. A review of biologic therapies targeting IL-23 and IL-17 for use in moderate-to-severe plaque psoriasis. *Dermatol Ther (Heidelb)*. 2016;6(1):1–12.
83. Mease PJ, Genovese MC, Greenwald MW, Ritchlin CT, Beaulieu AD, Deodhar A, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. *N Engl J Med*. 2014;370(24):2295–306.
84. Chiricozzi A, Krueger JG. IL-17 targeted therapies for psoriasis. *Expert Opin Investig Drugs*. 2013;22(8):993–1005.
85. Marzo-Ortega H, Sieper J, Kivitz A, Blanco R, Cohen M, Delicha EM, et al. Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2. *RMD Open*. 2017;3(2):e000592.

<https://doi.org/10.1186/s40779-022-00382-3>

**Cite this article as:** Nie YJ, Wu SH, Xuan YH, Yan G. Role of IL-17 family cytokines in the progression of IPF from inflammation to fibrosis. *Mil Med Res*. 2022;9(1):21.